Mobile Courant

U.S. Senator Tommy Tuberville (R-AL) has joined U.S. Senator Rand Paul (R-KY) in a resolution of disapproval under the Congressional Review Act (CRA) to oppose the Medical Devices: Laboratory Developed Tests (LDTs) rule recently finalized by the Food and Drug Administration (FDA). The final rule, published on May 6th, seeks to impose regulations on the creation and implementation of LDTs, potentially limiting patients' access to critical diagnostic testing. These tests are already regulated by the Centers for Medicare & Medicaid Services, and Congress has not granted the FDA authority over lab tests.

"Yet again, the Biden administration is exercising executive overreach," said Senator Tuberville. "Excessive regulations on LDTs pose a risk of delaying vital diagnostics patients critically need. Alabama hospitals use these tests every day, and I will fight to ensure Alabamians get the best care possible in our medical centers."

Senator Tuberville was joined by Senators Marsha Blackburn (R-TN), Ted Budd (R-NC), Katie Britt (R-AL), Bill Cassidy (R-LA), and Eric Schmitt (R-MO) in introducing this legislation. In parallel, U.S. Representative Brad Finstad (R-MN-01) introduced a companion resolution in the U.S. House of Representatives.

Lab tests are often considered essential within the U.S. healthcare system for providing timely results to patients with rare diseases and conditions.

Senator Tommy Tuberville represents Alabama in the United States Senate and serves on several committees including Armed Services, Agriculture, Veterans’ Affairs, and HELP Committees.